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Evaluation of radiotherapy techniques for radical treatment of lateralised 
oropharyngeal cancers: Dosimetry and NTCP 
 
	
	
Zusammenfassung:	
Ziel:	
Das	 Ziel	 dieser	 Studie	 ist	 die	 Untersuchung	 potenzieller	 Vor-	 und	Nachteile	 verschiedener	
moderner	Bestrahlungstechniken	 für	die	 ipsilaterale	Bestrahlung	von	Oropharynx-Tumoren	
hinsichtlich	 der	 resultierenden	 Dosisverteilung	 im	 Planungszielvolumen	 (PTV),	 den	
Risikoorganen	 (OARs)	und	der	Komplikationswahrscheinlichkeit	 in	Normalgeweben	 (NTCP).	
Im	Rahmen	dieser	Analyse	wird	die	dreidimensionale,	konformale	Strahlentherapie	(3DCRT),	
die	 intensitätsmodulierte	 Strahlentherapie	 (IMRT)	 in	 Step-and-Shoot	 Technik	 und	 die	
intensitätsmodulierten	Rotationstherapie	(volumetric	arc,	VMAT)	verglichen.	
	
	
	
Materialen	und	Methoden:	
Im	Rahmen	einer	Planungsstudie	 für	die	Primärtherapie	unterschiedlicher	 Fälle	 von	 streng	
unilateralen	Oropharynx-Tumoren	wurden	 Dosisverteilungen	 von	 3DCRT,	 IMRT	 und	 VMAT	
anhand	verschiedener	Parameter	miteinander	verglichen.	Hierfür	wurden	Konformitätsindex	
(CI),	Homogenitätsindex	(HI),	Dosis-Volumen-	Histogramme	(DVHs)	des	PTVs	und	der	OARs,	
NTCP,	 Risiko	 von	 strahleninduzierten	 Zweittumoren	 und	 die	 aufsummierte	 applizierte	
Gesamtdosis	untersucht.	
	
Ergebnisse:	
Die	 Bestrahlungspläne	 von	 IMRT	 und	 VMAT	 waren	 im	 Bezug	 auf	 den	 CI,	 HI,	 die	
Dosisverteilung	 im	 Zielvolumen	 und	 im	 Unterkiefer	 sowie	 in	 der	 tatsächlich	 applizierten	
Dosis	 der	 3DCRT	 überlegen.	 Bezüglich	 der	 Dosisverteilung,	 der	 NTCP	 der	 kontralateralen	
Mundhöhle	 und	 des	 Unterkiefers	 bei	 Anwendung	 einer	 dedizierten	 Dosisvolumen-
Beschränkung	 der	 Mundhöhle	 konnten	 keine	 Unterschiede	 zwischen	 den	
Bestrahlungstechniken	festgestellt	werden.	Obwohl	das	Niedrigdosis-Volumen	bei	IMRT	und	
VMAT	 signifikant	 höher	 war	 als	 bei	 3DCRT,	 ist	 das	 erwartete	 Risiko	 strahleninduzierter	
Zweittumoren	abhängig	vom	verwendeten	mathematischen	Modell.	
	
Schlussfolgerung:	
Die	 untersuchten	 IMRT/VMAT	 Techniken	 sind	 der	 3DCRT	 bei	 der	 Bestrahlung	 streng	
unilateraler	 oropharyngealer	 Tumore	 in	 Bezug	 auf	 die	Dosishomogenität,	 Konformität	 und	
konsistenten	 Bestrahlung	 des	 PTV	 während	 der	 gesamten	 Behandlungsdauer	 überlegen.	
Dosimetrie	 und	NTCP	 Berechnungen	 zeigen,	 dass	 diese	 Techniken	 in	 Bezug	 auf	 das	 Risiko	
einer	 akuten	 Mukositis	 bei	 Anwendung	 einer	 spezifischen	 Dosisbeschränkung	 auf	 die	
kontralateralen	Mundhöhle	äquivalent	zu	3DCRT	sind.	
	
Abstract	
	
Aim:	
	
The	aim	of	 this	 study	was	 to	 investigate	potential	 advantages	and	disadvantages	of	 three-
dimensional	 (3D)-conformal	 technique	 (3DCRT),	 multiple	 fixed-field	 intensity-modulated	
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radiotherapy	(referred	to	as	IMRT	hereafter)	and	volumetric	modulated	arc	therapy	(VMAT)	
in	 terms	 of	 dose	 to	 the	 planning	 target	 volume	 (PTV),	 organs	 at	 risk	 (OARs),	 and	 normal	
tissue	complication	probability	(NTCP)	for	delivering	ipsilateral	radiotherapy.		
Materials	and	methods:		
We	 compared	 3DCRT,	 IMRT	 and	 VMAT	 in	 patients	 with	 well-lateralised	 primary	 tonsillar	
cancers	who	underwent	primary	 radical	 ipsilateral	 radiotherapy.	 The	 following	parameters	
were	 compared:	 conformity	 index	 (CI),	 homogeneity	 index	 (HI),	 dose	 volumes	 histograms	
(DVHs)	 of	 PTVs	 and	OARs,	 normal	 tissue	 complication	 probability	 (NTCP),	 risk	 of	 radiation	
induced	cancer	and	dose	accumulation	during	treatment.		
Results:	
IMRT	and	VMAT	were	superior	to	3DCRT	in	terms	of	CI,	HI,	dose	to	the	target	volumes	and	
mandible	and	dose	accumulation	 robustness.	 	The	 techniques	were	equivalent	 in	 terms	of	
dose	and	NTCP	for	contralateral	oral	cavity,	contralateral	submandibular	gland	and	mandible	
when	specific	dose	constraint	objectives	were	used	on	the	oral	cavity	volume.	Although	the	
volume	of	normal	 tissue	exposed	 to	 low	dose	 radiation	was	 significantly	higher	with	 IMRT	
and	 VMAT,	 the	 risk	 of	 radiation	 induced	 second	 malignancy	 was	 dependant	 on	 the	
mathematical	model	used.		
Conclusion:		
This	study	demonstrates	the	superiority	of	 IMRT/VMAT	techniques	over	3DCRT	in	terms	of	
dose	 homogeneity,	 conformity	 and	 consistent	 dose	 delivery	 to	 the	 PTV	 throughout	 the	
course	 of	 treatment	 for	 patients	 with	 lateralised	 oropharyngeal	 cancers.	 Dosimetry	 and	
NTCP	calculations	show	that	these	techniques	are	equivalent	to	3DCRT	in	regard	to	the	risk	
of	acute	mucositis	when	specific	dose	constraint	objectives	were	used	on	a	contralateral	oral	
cavity	OAR.			
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Introduction	
	
Radiotherapy	 to	 the	 ipsilateral	 oropharynx	 and	 neck	 is	 a	 well-established	 treatment	
technique	 for	 patients	 with	 well-lateralised	 tonsillar	 squamous	 cell	 carcinomas	 1-6.	 An	
acceptable	rate	(2-8%)	of	contralateral	nodal	recurrence	in	a	carefully	selected	population	is	
supported	by	published	evidence	 in	 the	 form	of	 single	 centre	 retrospective	 case	 series	 1-6.	
The	 rationale	 behind	 using	 an	 ipsilateral	 technique	 is	 to	 achieve	 sparing	 of	 contralateral	
normal	structures;	 the	parotid	salivary	gland,	 in	particular,	 reducing	the	rates	of	 long-term	
xerostomia	 and	 its	 associated	 morbidities.	 This	 improves	 quality	 of	 life	 in	 survivors	 5.	 In	
addition,	it	is	presumed	that	the	lower	dose	is	delivered	to	the	contralateral	oral	cavity	and	
mandible,	 reduces	 the	 rates	 of	 acute	 oral	 mucositis	 and	 mandibular	 osteoradionecrosis	
(ORN)	1,2,4.	
	
Two	 or	 three	 ipsilateral	 wedged	 fields	 with	 (3DCRT)	 or	 inverse	 planning	 tecniques	
(IMRT/VMAT)	 can	 be	 used	 to	 deliver	 ipsilateral	 radiotherapy.	 	 In	 the	 published	 studies	 of	
ipsilateral	 radiotherapy,	 some	 centres	 have	 used	 3DCRT	 1,4,6,	 some	 centres	 have	 used	
(IMRT/VMAT)		2	and	some	centres	historically	used	3DCRT	and	converted	to	IMRT/VMAT	3.	
When	 treating	 non-lateralised	 tumours	 of	 the	 oropharynx,	 the	 advantages	 of	 IMRT	
techniques	(multiple-field	and	arc	therapy)	in	sparing	parotid	gland	and	constrictor	muscles	
are	 well	 proven	 7,8.	 Such	 techniques	 represent	 the	 standard	 of	 care	 in	 the	 majority	 of	
radiotherapy	 departments.	 	 In	 contrast,	 there	 is	 a	 lack	 of	 evidence	 to	 support	 the	 use	 of	
IMRT/VMAT	techniques	over	3DCRT	when	treating	well-lateralised	oropharyngeal	tumours.		
They	use	two	to	three	times	more	monitor	units,	which	results	in	increased	total	body	dose	
due	 to	 increased	 radiation	 leakage.	 Optimal	 organ	 sparing	 using	 inverse	 techniques	
necessitates	 the	use	of	more	 treatment	 fields,	which	 results	 in	 a	 larger	 volume	of	 normal	
tissue	 exposed	 to	 a	 low	 radiation	 dose.	 These	 factors	 can	 potentially	 increase	 the	 risk	 of	
acute	 radiation	 toxicity	 and	 of	 radiation-induced	 malignancies	 by	 two-fold	 compared	 to	
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3DCRT	9.	Quantification	of	predicted	NTCP	for	3DCRT	and	IMRT/VMAT	will	aid	the	choice	of	
optimal	treatment	technique	in	the	setting	of	ipsilateral	irradiation.		
	
The	specific	aim	of	this	study	was	to	demonstrate	the	potential	dosimetric	advantages	(or	at	
least	 equivalence)	 of	 the	 IMRT	 techniques	 (using	 precise	 well	 defined	 optimisation)	
compared	to	3DCRT	in	terms	of	dose	to	the	PTV,	OARs,	and	NTCP	(including	risk	of	second	
malignancy)	 for	 treatment	 of	 well-lateralised	 oropharyngeal	 SCC,	 before	 implementation	
into	 clinical	 practice.	 The	 secondary	 aim	was	 to	 study	 the	 dosimetric	 effect	 of	 volumetric	
changes	during	treatment	for	each	of	these	three	techniques.		
		
	
Materials	and	Methods	
	
	
This	 was	 a	 non-interventional	 retrospective	 planning	 study	 in	 ten	 patients	 with	 well-
lateralised	primary	tonsillar	cancers	who	underwent	primary	radical	ipsilateral	radiotherapy	
at	 our	 institute.	 The	 cases	 selected	 for	 this	 study	 had	 well-lateralised	 SCC	 of	 the	 tonsil	
(T1/T2,	N0-N2b).	 	 Tonsillar	 cancer	without	 involvement	of	 soft	palate	or	base	of	 tongue	 is	
defined	as	“well-lateralised”	according	to	our	 institutional	protocol.	All	patients	had	a	high	
risk	of	metastases	or	involvement	of	ipsilateral	cervical	lymph	nodes	and	therefore	required	
ipsilateral	 neck	 irradiation.	 All	 patients	 underwent	 a	 diagnostic	 tonsillectomy	 prior	 to	
radiotherapy,	which	is	standard	practice	across	the	majority	of	centres.		Five	of	the	patients	
were	treated	with	3DCRT	and	the	remaining	cases	were	treated	with	VMAT.		The	variation	in	
treatment	technique	was	as	a	result	of	patients	being	treated	at	two	different	 locations	at	
our	institute.		All	patients	were	treated	with	doses	of	65	Gy	in	30	fractions	(2.17	Gy/fraction)	
over	6	weeks	to	the	primary	target	(PTV1).	Doses	to	the	elective	target	(PTV2)	were	54	Gy	in	
30	 fractions	 (1.8	 Gy/fraction)	 over	 six	 weeks	 for	 VMAT	 and	 50	 Gy	 in	 25	 fractions	 (2	
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Gy/fraction)	over	 five	weeks	 for	3DCRT.	Patients	with	node	positive	disease	and	under	the	
age	of	seventy-one	years	received	platin-based	concomitant	chemoradiotherapy.		
	
	
	
	
Target	volume	delineation	
	
	
All	 patients	 were	 treated	 in	 a	 standard	 thermoplastic	 shell.	 Planning	 CT	 scans	 at	 2	mm	
intervals	 were	 obtained.	 Clinical	 target	 volume	 (CTV)	 1	 included	 gross	 tumour	 volume	
(GTV)	 plus	 a	 1	 cm	 isotropic	 margin	 plus	 ipsilateral	 level	 Ib,	 IIa	 and	 any	 involved	 lymph	
nodes.	 	Uninvolved	barriers	 to	tumour	spread,	such	as	bone	and	fasciae,	were	excluded.	
The	 elective	 nodal	 volume	 (CTV2)	 included	 uninvolved	 levels	 III–V	 and	 supraclavicular	
fossa	 (SCF)	 nodes	 ipsilaterally.	 Delineation	 was	 performed	 according	 to	 the	 consensus	
guidelines	 10,11.	 A	 3	mm	 isotropic	margin	was	 added	 to	 the	 CTVs	 to	 obtain	 the	 planning	
target	 volumes	 PTVs	 12.	 Organ-at-risk	 (OAR)	 volumes	 for	 spinal	 cord,	 brainstem,	 parotid	
salivary	 glands,	 lenses,	 optic	 nerves,	 and	 optic	 chiasm	 were	 routinely	 delineated.	 	 In	
addition,	contralateral	and	ipsilateral	mandible,	contralateral	oral	cavity,	contralateral	sub-
mandibular	gland	(SMG)	and	posterior	fossa	were	delineated	on	the	CT	by	an	experienced	
clinical	 oncologist	 (SB).	 The	 sections	 of	 the	mandible	 ipsilateral	 and	 contralateral	 to	 the	
side	of	the	tumour,	with	the	mid-line	as	the	medial	border	were	delineated	as	 ipsilateral	
and	 contralateral	 mandible,	 respectively.	 The	 surfaces	 of	 the	 inner	 table	 of	 mandible,	
tongue,	floor	of	mouth	and	hard	palate	with	the	medial	border	at	mid-line	at	a	distance	of	
1cm	from	the	PTV	were	outlined	as	the	contralateral	oral	cavity.		The	remaining	volume	at	
risk	 (RVR)	 was	 defined	 as	 the	 remaining	 non-contoured	 normal	 tissue.	 Hippocampal	
structures	were	delineated	using	atlas-based	methods	13.	
	
Treatment	planning	methods	
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Radiotherapy	plans	were	generated	using	the	Philips	Pinnacle3	v9.6	(Philips,	Fitchburg,	WI)	
treatment	planning	system	(TPS).	IMRT	and	VMAT	plans	were	retrospectively	generated	for	
cases	that	were	initially	treated	using	3DCRT,	and	IMRT	and	3DCRT	plans	were	produced	for	
patients	treated	using	VMAT.	
	
3DCRT	was	planned	using	a	single	isocentre	anterior-oblique	and	posterior-oblique	wedged	
pair	to	encompass	the	CTV1.		The	Ipsilateral	lower	neck	was	treated	with	a	matched	anterior	
and	 posterior	 parallel	 opposed	 fields.	 A	 low	 weighted	 lateral	 beam	 was	 typically	 used	
together	with	the	wedged-pair	in	order	to	ensure	the	dose	within	the	target	remained	below	
107%	of	that	prescribed.		Both	IMRT	and	VMAT	plans	were	optimised	by	the	Pinnacle3	TPS	
to	ensure	that	the	clinical	dose	objectives	were	satisfied	(Table	1).		VMAT	plans	consisted	of	
partial	arcs	varying	 from	90	 to	105	control	points	with	2⁰	control	point	 spacing,	optimised	
using	Pinnacle’s	SmartArc	algorithm.	 	The	fixed-field	 IMRT	plans	consisted	of	five	co-planar	
beams	with	a	maximum	of	50	control	points	in	total.	 	Pinnacle’s	Direct	Machine	Parameter	
Optimisation	(DMPO)	was	used	to	generate	the	individual	control	point	shapes	and	weights	
of	the	IMRT	plans.		PTV	ring	structures	and	other	‘optimisation’	regions	of	interest	(ROIs)	(in	
otherwise	non-contoured	tissue)	were	used	in	VMAT	and	IMRT	inverse	planning	in	order	to	
generate	 conformal	 plans	 with	 reduced	 RVR	 integral	 dose.	 VMAT	 and	 IMRT	 plans	 were	
further	 optimised	 with	 a	 constraint	 of	 maximum	mean	 dose	 of	 36	 Gy	 (based	 on	 average	
mean	dose	from	the	3DCRT	plans,	Table	2)	on	the	contralateral	oral	cavity	volume.		
	
	
Treatment	plan	evaluation	
	
	
Coverage	of	PTVs	was	evaluated	using	 volume	 receiving	95%	of	 the	prescribed	dose	 (V95);	
and	dose	distribution	to	PTV1	was	further	evaluated	using	the	Paddick	conformity	index	(CI)	
and	 the	 homogeneity	 index	 (HI).	 CI	 was	 defined	 as,	 CI	 =	 ([TV(PIV)]2)/[TV*V(RI)],	 where	
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TV(PIV),	TV,	and	V(RI)	are	the	volumes	of	the	target	covered	by	the	95%	isodose,	the	target	
volume,	and	the	total	volume	covered	by	the	95%	 isodose	[11].	 	Perfectly	conformal	plans	
have	CI	=	1,	whilst	smaller	CI	values	correspond	to	less	conformal	dose	distributions.	HI	was	
defined	 as,	 HI	 =	 (D2	 –	 D98)/Dmedian,	 where	 D2	 and	 D98	 are	 the	 maximum	 and	 minimum	
doses,	respectively	14.		Smaller	HI	values	correspond	to	more	homogeneous	plans	with	HI	=	0	
corresponding	 to	 absolute	 homogeneity	 within	 the	 target	 volume.	 Dose	 to	 OARs	 were	
evaluated	using	the	following	dosimetric	criteria:	clinical	dose	objectives	(Table	1),	mean	and	
maximum	dose	(D2-dose	to	2%	volume)	to	the	ipsilateral	and	contralateral	mandible,	mean	
dose	 contralateral	 oral	 cavity,	 contralateral	 SMG	and	posterior	 fossa.	 	 The	 volume	of	 RVR	
receiving	 10	 Gy	 was	 also	 assessed.	 Dose	 cubes	 were	 exported	 from	 Pinnacle	 to	 the	
RayStation	 TPS	 (RaySearch	 Laboratories,	 Stockholm,	 Sweden)	 in	 order	 to	 generate	 dose	
difference	maps.	
	
NTCP	calculations:	
	
The	 doses	 to	 bilateral	 hippocampi	 and	 contra-lateral	 oral	 cavity	 were	 converted	 to	 the	
equivalent	dose	 in	2	Gy	fractions	(EQD2)	using	the	Withers	 formula	and	α/β	=	2	15	and	10,	
respectively	16.	The	probability	of	neurocognitive	function	(NCF)	 impairment	was	evaluated	
using	the	NTCP	model	described	by	Gondi	et	al15,	where	the	probability	of	a	decline	in	short-
term	memory	function,	as	measured	by	the	Wechsler	Memory	Scale-III	Word	Lists	delayed	
recall	at	18	months	post-RT,	is	related	to	the	bilateral	hippocampal	EQD2	D40.		The	NTCPs	of	
grade	 3	 dysphagia	 and	 grade	 3	 oral	 mucositis	 were	 predicted	 according	 to	 the	 models	
derived	by	Bhide	et	al	17.		
	
Probability	of	secondary	cancers	
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The	 probability	 of	 secondary	 cancers	 was	 estimated	 using	 the	 dose	 to	 all	 normal	 tissue	
(whole	body	–	PTV).	 To	 capture	 the	 range	of	 possible	 estimates	of	 second	 cancer	 risk	 the	
probability	was	assessed	using	a	model	with	reducing	risk	for	higher	doses	where	the	risk	is	
assumed	to	fall	off	for	increasing	dose	with	D0=10	and	a	dose	plateau	model,	where	the	risk	
of	radiation	induced	cancer	is	postulated	to	plateau	beyond	a	threshold	dose	of	4	Gy		[7].	
	
	
Dose	accumulation	
	
	
Cone	Beam	CT	(CBCT)	images,	acquired	on	day	1-3	and	at	weekly	intervals	thereafter,	were	
used	 to	 calculate	 dose	 accumulation	 for	 each	 of	 the	 plans.	 CBCT	 images	 lack	 sufficient	
quality	 for	 use	 in	 dose	 calculation	 so	 the	 images	were	 post	 processed	 to	 remove	 scatter,	
using	 data	 from	 the	 patients’	 planning	 CTs	 [11].	 In	 addition,	 to	 correct	 for,	 when,	 the	
patient's	 shoulders	and	 top	of	head	were	outside	 the	 field	of	 view	 (FOV)	of	 the	CBCT,	 the	
FOV	was	increased	and	these	structures	were	mapped	to	the	CBCT	from	the	planning	CT	and	
the	Hounsfield	units	were	 set	 to	values	 for	 soft	 tissue.	 In	addition,	 the	patient’s	 shoulders	
and	 top	 of	 head,	 which	 were	 outside	 the	 imaged	 field	 of	 view	 (FoV)	 on	 treatment,	 were	
outlined	 on	 the	 planning	 CT	 and	mapped	 across	 to	 the	 on-treatment	 images	with	 density	
overrides	applied	to	the	body	tissue	outside	of	the	CBCT	FoV.	3DCRT,	IMRT,	and	VMAT	plans	
were	 then	 calculated	 in	 each	 of	 the	 manifested	 patient	 geometries	 observed	 during	
treatment.	 The	 CBCT	 images	 were	 deformably	 registered	 with	 the	 planning	 CT	 using	 the	
ANACONDA	18	algorithm	available	within	the	RayStation®	TPS.	The	deformations	were	then	
applied	to	the	dose	cube	calculated	on	the	CBCT	to	enable	dose	summation	and	therefore	
allowing	us	 to	 calculate	 an	estimate	of	 the	delivered	accumulated	dose.	 Estimates	 for	 the	
changes	 in	 the	 dose	 to	 target	 volumes	 and	 OARs,	 from	 planning	 to	 treatment	 were	 then	
quantified.			
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Data	analysis	
	
	
Statistical	 data	 analysis	 was	 performed	 using	 R	 (R	 Foundation	 of	 Statistical	 Computing,	
Vienna,	Austria)	and	Microsoft	Excel (Redmond,	WA,	US).			Wilcoxon	signed-rank	tests	were	
used	 to	 compare	 differences	 between	 3DCRT,	 IMRT,	 and	 VMAT	 plans,	 with	 a	 statistical	
significance	level	of	alpha=0.05.	
	
	
	
	
	
	
	
Results	
	
	
A	 statistically	 significant	 (p-values	 Table	 2),	 higher	 percentage	 volume	 of	 PTV	 1	 and	 2,	
respectively,	received	95%	of	the	prescribed	dose	(V95)	when	using	IMRT	(97%	and	98%)	and	
VMAT	(97%	and	97%)	as	opposed	to	3DCRT	(92%	and	89%)	(Table	2).	In	addition,	the	IMRT	
(0.8	 and	 0.1)	 and	 VMAT	 (0.8	 and	 0.1)	 plans	 were	 more	 conformal	 and	 homogenous	
compared	 to	 3DCRT	 (0.6	 and	 0.2),	 based	 on	 the	 superior	 CI	 and	 HI,	 respectively.	 The	
differences	between	the	doses	to	PTV’s,	CI	and	HI	were	statistically	significant	(Table	2).	The	
There	was	no	 statistical	difference	 in	 the	V95,	HI	 and	CI	between	 IMRT	and	VMAT	plan	 (p-
values	Table	2).	
Maximum	 doses	 to	 the	 spinal	 cord	 and	 brainstem,	 respectively,	 were	 significantly	 higher	
with	IMRT	(43	Gy,	p	=	0.008	and	46	Gy,	p	=	0.002)	and	VMAT	(42	Gy,	p	=	0.004	and	44	Gy,	p	=	
0.002)	 compared	 to	 3DCRT	 (36	 Gy	 and	 35	 Gy)	 (Table	 2).	 However,	 these	 were	 within	
published	tolerance	values	19,20.	The	mean	dose	and	percentage	volume	receiving	60	Gy	(V60)	
to	the	ipsilateral	mandible	was	significantly	lower	with	IMRT	and	VMAT	versus	3DCRT		(Table	
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2	 for	 p-values).	 	 The	 posterior	 fossa	D50	 dose	was	 significantly	 higher	with	 3DCRT	 (17	Gy)	
versus	IMRT	(12	Gy,	p	=	0.01)	and	VMAT	(10	Gy,	p	=	0.01).		
	
3DCRT	 resulted	 in	 lower	 mean	 doses	 to	 the	 contralateral	 OARs,	 when	 using	 standard	
optimisation	 ROIs	 However,	 when	 the	 IMRT	 and	 VMAT	 plans	 were	 re-optimised	 with	 a	
constraint	on	the	contralateral	oral	cavity	volume,	the	differences	between	the	mean	doses	
to	the	contralateral	oral	cavity	were	non-significant,	without	dose	compromise	for	PTV1	and	
PTV2	(Table	2	for	dose	statistics	and	p-values).	The	3DCRT	and	IMRT	plans	were	significantly	
superior	 to	 the	VMAT	plans	 for	dose	 to	 the	 contralateral	mandible	 (Table	2).	3DCRT	plans	
remained	 significantly	 superior	 for	 contralateral	 parotid	 sparing.	 	 	 However,	 dose	 to	 the	
contralateral	 SMG	was	 not	 significantly	 lower	 with	 3DCRT	 when	 plans	 were	 re-optimised	
with	the	specific	oral	cavity	constraint.		
	
3DCRT	(2011cm3)	delivered	the	lowest,	statistically	significant	volume	of	RVR	receiving	10	Gy	
compared	 to	 IMRT	 (3042cm3,	 p	 =	 0.002)	 and	 VMAT	 (2767cm3,	 p	 =	 0.002).	 	 VMAT	 was	
superior	to	IMRT	(p=0.01),	Table	2.		
	
	
	
NTCP	calculations	(Table	3)	
	
There	 was	 no	 significant	 difference	 between	 the	 three	 techniques	 for	 probability	 of	 NCF	
impairment	based	on	NTCP	calculations	(Table	3).	The	probability	of	grade	3	oral	mucositis	
and	grade	3	dysphagia	were	 significantly	 lower	 for	3DCRT	 for	plans	without	a	 specific	oral	
cavity	constraint.	When	a	specific	oral	cavity	constraint	was	used,	the	apparent	advantage	of	
3DCRT	disappeared.	However,	the	IMRT	technique	maintained	its	significant	advantage	over	
VMAT.		
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Radiation-induced	cancers	(table	3)	
	
The	predicted	probabilities	of	radiation-induced	cancers	depend	on	the	applied	model	and	
are	 always	 higher	 for	 IMRT	 and	VMAT	 than	 3DCRT.	 	 always	 resulting	 in	 higher	 risk	 values	
than	 that	 for	 3DCRT.	 	 However,	 differences	 between	 the	 planning	 techniques	 were	 not	
statistically	significant	(Table	3).		
	
Dose	accumulation	(table	4)	
	
	
Data	on	estimates	of	change	in	dose	from	planned	to	treatment	were	available	for	eight	of	
the	 ten	patients.	 	 Image	quality	of	 the	CBCT	 in	 two	patients	was	deemed	unsatisfactory	 in	
spite	 of	 the	 scatter	 corrections	 and	 these	 were	 excluded	 from	 the	 analyses.	 	 Statistically	
significant	reduction	in	the	D95	for	CTV1	was	observed	for	all	3DCRT	(3.5	Gy),	IMRT	(1.9	Gy)	
and	 VMAT	 (1.9	 Gy)	 plans	 with	 the	 largest	 reduction	 observed	 for	 3DCRT.	 A	 statistically	
significant	 increase	 of	 approximately	 1	 Gy	 in	 both,	 the	 brain	 stem	 (D0.1cm3)	 and	 posterior	
fossa	(mean	dose),	was	measured	for	IMRT	and	VMAT	as	compared	to	the	original	treatment	
plan.	 	 Additionally,	 3DCRT	 resulted	 in	 a	 significant	 (p	 =	 0.014)	 reduction	 in	 elective	 target	
(CTV2)	coverage.	
	
	
Discussion	
	
	
This	study	demonstrates	that	IMRT	and	VMAT	resulted	in	improved	dose	conformity	(CI)	and	
homogeneity	 to	both	primary	 and	elective	 targets.	However,	 this	was	at	 the	expense	of	 a	
higher	 dose	 to	 the	 contralateral	 oral	 cavity,	 when	 using	 standard	 ‘optmisation’	 ROIs	 for	
inverse	 planning.	 IMRT	 and	 VMAT	 were	 equivalent	 to	 3DCRT	 for	 contralateral	 oral	 cavity	
sparing	when	optimised	using	a	specific	dose	constraint	of	<36	Gy	to	the	contralateral	oral	
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cavity,	 without	 affecting	 PTV.	 	 This	 is	 reflected	 in	 the	 NTCP	 calculations	 with	 equivalent	
probabilities	of	acute	mucositis	for	the	re-optimised	plans.		
	
The	mean	 dose	 and	 V60	 to	 the	 ipsilateral	mandible	were	 significantly	 lower	 for	 IMRT	 and	
VMAT,	 Table	 2.	 A	 study	 of	 30	 patients	 with	 ORN	 (out	 of	 total	 of	 402	 patients	 with	
oropharyngeal	cancer)	demonstrated	V50	and	V60	as	a	significant	factor	for	development	of	
ORN	21.	Grade	4	ORN	in	that	study	manifested	on	the	side	ipsilateral	to	disease	with	a	mean	
dose	 to	 the	 ipsilateral	mandible	of	 66	Gy	 in	patients	who	developed	ORN.	 Lee	et	 al.	 have	
shown	 that	 a	mean	 dose	 of	 >54	 Gy	 (1.8	 Gy	 per	 fraction)	 predicts	 for	 ORN	 22.	 	 Therefore,	
lower	mean	dose	and	V60	achieved	with	IMRT	and	VMAT	should	reduce	the	incidence	of	ORN	
compared	 to	 3DCRT	 in	 the	 ipsilateral	 mandible.	 Indeed,	 results	 from	 retrospective	 series	
reviews	 (bilateral	 irradiation)	 with	 historical	 controls	 for	 comparison	 suggest	 that	 the	
incidence	of	ORN	is	lower	with	IMRT	techniques	23,24.		
	
The	mean	dose	to	the	contralateral	parotid	gland	was	significantly	lower	with	3DCRT	(5.6	Gy)	
compared	to	VMAT	(11.8	Gy)	and	IMRT	(15.9	Gy).	The	mean	dose	with	all	three	techniques	
was	lower	than	the	26	Gy	threshold	for	<25%	reduction	in	parotid	function,	reported	in	the	
landmark	 Eisbruch	 study	 25.	 	 The	predicted	 risk	of	 late	 grade	2	 xerostomia	 is	 less	 than	5%	
with	 3DCRT	 and	 VMAT	 based	 on	 the	 dose	 response	 curves	 reported	 by	 Houweling	 et.	 al.	
using	larger	patient	dataset	(including	the	one	used	in	the	Eisbruch	study).		In	addition,	there	
was	no	significant	difference	in	the	dose	to	the	contralateral	SMG,	when	IMRT/VMAT	plans	
were	 re-optimised	 using	 specific	 dose	 constraints.	 The	 SMG	 contributes	 majority	 of	 the	
mucin	 rich	 saliva	 in	 unstimulated	 state	 and	 determines	 patient	 reported	 xerostomia	
following	 radiotherapy	 26.	Therefore,	3DCRT	and	 IMRT/VMAT	are	 likely	 to	be	equivalent	 in	
terms	of	the	late	patient	reported	xerostomia	scores.		
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IMRT	techniques	resulted	in	a	statistically	significant	increase	in	the	volume	of	normal	tissue	
receiving	low	dose	radiation	(table	2).	There	are	two	reasons	why	the	change	from	3DCRT	to	
IMRT	may	result	in	an	increase	in	second	malignancies.	First,	IMRT	involves	the	use	of	more	
fields,	and	as	a	consequence,	a	bigger	volume	of	normal	 tissue	 is	exposed	 to	 lower	doses.	
Second,	 this	 risk	may	be	higher	due	 to	 the	 increased	 scatter	 associated	with	use	of	 IMRT.		
This	scattered	radiation	is	made	up	of	three	components,	internal	patient	scatter,	collimator	
scatter,	and	head	 leakage.	The	first	 two	of	these	are	probably	 lower	with	 IMRT	due	to	the	
reduced	high	dose	field	sizes	and	reduced	intensity	of	the	individual	beam.	The	head	leakage	
is	responsible	only	for	scatter	radiation	>15-30	cm	from	the	treatment	area	27.		The	radiation	
dose	 to	 distant	 tissues	 from	 head	 leakage	 is	 very	 low	 and	 data	 from	 clinical	 and	
experimental	 studies	 suggest	 that	 risk	 from	 doses	 <0.15	 Gy	 is	 negligible	 28.	 Nevertheless,	
IMRT	 delivery	 requires	 increased	 number	 of	 monitor	 units,	 resulting	 in	 increased	 head	
scatter	and	the	potential	risks	from	this	cannot	be	ignored.	Rubens	et	al.	modeled	the	risk	of	
radiation-induced	 cancer	 with	 IMRT	 from	 increased	 head	 scatter	 and	 predicted	 for	 a	
negligible	 risk	 in	 IMRT	 treatment	plans	 requiring	2-4	 times	higher	monitor	units.	The	head	
leakage	is	hardware-	and	software-dependent	with	variation	among	treatment	centres	29.	
The	 probability	 of	 developing	 second	malignancy	 as	 a	 result	 of	 low	 dose	 irradiation	 to	 a	
greater	volume	 in	proximity	of	treatment	fields	depends	on	the	model	applied.	 It	 is	higher	
when	using	 “the	plateau	model	of	 risk”	as	opposed	 to	 the	 “reducing	 risk	 at	higher	doses”	
model.		We	have	used	radiocarcinogenesis	models	of	Hall	et	al	9.	Equivalent	risks	observed	in	
our	study	with	“reducing	risk	at	higher	doses”	contradict	the	findings	of	the	Hall	study.	The	
study	by	Rubens	et	al.	who	also	modelled	the	risk	using	measurements	of	dose	in	phantom	
to	 tissues	within	 the	 proposed	 target	 volumes	 for	 various	 possible	 treatment	 sites,	which	
included	 tonsillar	 and	 nasopharyngeal	 cancer	 failed	 to	 demonstrate	 increased	 risk	 with	
either	of	these	models	29.	Given	the	uncertainties	in	the	model	of	second	cancer	risk,	more	
research	in	this	area	is	required	prior	to	drawing	definite	conclusions	28.		
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Dose	 accumulation	 calculations	 demonstrate	 that	 the	mean	D95	 to	 CTV1	 throughout	 the	 6	
weeks	of	treatment	was,	on	average,	1.6	Gy	lower	for	3DCRT	plans	compared	to	both	IMRT	
and	VMAT.	The	IMRT	techniques	resulted	in	1	Gy	higher	dose	to	the	brain	stem,	which	did	
not	 exceed	 the	 dose	 constraints.	 The	 radiobiological	 and	 clinical	 significance	 of	 these	
findings	is	unclear.	 It	should	be	noted,	however,	that	 in	spite	of	the	absence	of	statistically	
significant	 differences	 between	 treatment	 techniques,	 the	 difference	 for	 an	 individual	
patient	might	still	be	clinically	significant.	
	
Conclusion:	
	
This	study	demonstrates	that	VMAT,	that	is	highly	optimised	to	minimise	dose	deposition	in	
areas	outside	the	PTV,	is	the	best	technique	in	terms	of	dose	homogeneity,	conformity,	risk	
of	 ORN	 and	 consistent	 dose	 delivery	 to	 the	 PTV	 throughout	 the	 course	 of	 treatment	 for	
patients	with	lateralised	oropharyngeal	cancers.	Dosimetric	and	NTCP	calculations	show	that	
VMAT	 is	 equivalent	 to	3DCRT	 in	 regard	 to	 the	 risk	of	 acute	mucositis	 and	 late	 xerostomia	
with	specific	dose	constraints	on	a	contralateral	oral	cavity	OAR.			
The	likelihood	of	late	ORN	is	lower	with	IMRT/VMAT	techniques.	A	higher	volume	of	normal	
tissue	outside	the	PTV	is	exposed	to	a	low	radiation	dose	with	these	techniques,	which	may	
translate	 into	 a	 higher	 a	 risk	 of	 radiation-induced	malignancies	 depending	 on	 the	 applied	
radiobiological	model.		
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Figure	legends:	
	
Figure	1:		Isodose	distributions	for	3DCRT,	IMRT	and	VMAT	and	the	dose	difference	maps	of	
3DCRT	 versus	 IMRT	 and	 VMAT.	 Contours	 primary	 PTV	 (pink),	 contralateral	 oral	 cavity	
(green),	contralateral	parotid	(orange)	contralateral	mandible	(red),	and	spinal	cord	(white).	
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Figure	 2:	 Dose	 volume	 histograms	 for	 the	 treatment	 plans	 of	 all	 patients	without	 (A)	 and	
with	(B)	reoptimization	of	the	treatment	plan	using	36	Gy	as	an	additional	constraint	for	the	
contralateral	oral	cavity		
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Table	1:	Clinical	dose	objectives	for	IMRT	and	VMAT	treatment	plans	
 
Structure	 Dose	statistic	 Optimal	 Required	
PTV1		 Dose	to	99%	 	 >	58.5	Gy	(90%)	
PTV1		 Dose	to	95%	 	 >	61.8	Gy	(95%)	
PTV1		 Dose	to	50%	 	 65	+/-	1	Gy	
PTV1		 Dose	to	2	%	 	 <	69.5	Gy	(107%)	
PTV2		 Dose	to	99%	 	 >	48.6	Gy	(90%)	
PTV2		 Dose	to	95%	 	 >	51.3	Gy	(95%)	
PTV2		 Dose	to	50%	 	 54	+/-	1	Gy	
Bilateral	parotids	 Mean	dose	 <	24	Gy	 <	30	Gy	
Superficial	parotids	 Mean	dose	 <	24	Gy	 <	30	Gy	
Spinal	cord	 Maximum	point	dose	 	 <	46	Gy	
Spinal	cord	PRV	(+3mm)	 Maximum	point	dose	 	 <	48	Gy	
Brain	stem	 Maximum	point	dose	 	 <	50	Gy	
Brain	stem	PRV	(+3mm)	 Maximum	point	dose	 	 <	55	Gy	
Optic	chiasm	 Maximum	point	dose	 	 <	54	Gy	
Bilateral	optic	nerves	 Maximum	point	dose	 	 <	55	Gy	
Bilateral	lens	 Mean	dose	 	 <	6	Gy	
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Table	2:		Dose	statistics	for	3DCRT,	IMRT,	and	VMAT	plans	for	all	10	cases	with	optimisation	
using	standard	generic	optmisation	ROIs	and	additionally	with	specific	optimisation	
objectives	for	the	oral	cavity.			Mean	results	with	corresponding	Standard	Deviations	(SDs)	
are	shown	along	with	p-values	to	test	for	statistical	significance	between	the	planning	
techniques.	
	
	 3DCRT	 IMRT	 VMAT	 P-values,	Wilcoxon	signed-rank	test	
Target	Structure	 Dose	Statistic	 Mean	
(SD)	
Mean	
(SD)	
Mean	
(SD)	
3DCRT	Vs	
IMRT	
3DCRT	Vs	
VMAT	
IMRT	Vs	
VMAT	
PTV1	 V95	(%)	 92	(2.9)	 97	(1.3)	 97.0	(1.2)	 0.009	 0.002	 0.721	
PTV2	 V95	(%)	 89	(5.8)	 98	(1.3)	 97	(1.3)	 0.015	 0.015	 0.204	
Conformity	Index	(CI)	 Paddick	CI	 0.64	
(0.05)		
0.77	
(0.07)	
0.78	
(0.05)	
0.022	 0.014	 0.353	
Homogeneity	Index	(HI) (D2	–	D98)	/	D50 0.2	
(0.03)	
0.1	
(0.01)	
0.1	(0.01)	 0.002 0.002 0.919 
OAR	structure	 Dose	Statistic	 	 	 	 	 	 	
ipsi	parotid	 mean	(Gy)	 59	(6.2)	 55	(7.2)	 56	(6.8)	 0.016	 0.016	 0.800	
spinal	cord	 D2	(Gy)	 36	(3.3)	 43	(1.4)	 42	(2.1)	 0.008	 0.004	 0.048	
brain	stem		 D2	(Gy)	 35	(2.9)	 46	(1.6)	 44.0	(3.5)	 0.002	 0.002	 0.202	
post	fossa	 D50(Gy)	 17	(4.5)	 12	(4.2)	 10	(3.3)	 0.010	 0.010	 0.010	
ipsi	mandible	 mean	(GY)	 57	(2.9)	 55	(3.9)	 55	(3.2)	 0.037	 0.037	 0.444	
ipsi	mandible	 V60	(%)	 71	(8.7)	 53	(16.8)	 51	(15.6)	 0.002	 0.002	 0.322	
Ipsi	mandible	 D2	(Gy)	 66	(0.7)	 66	(1.0)	 66	(1.0)	 0.492	 0.438	 0.052	
RVR	 V10	(cm
3)	 2011.0	
(502)	
3042.0	
(1030)	
2767.0	
(879)	
0.002	 0.002	 0.010	
Generic	Optimisation	Volumes	 	 	 	 	 	 	
Contra	oral	cavity	
	
mean	(Gy)	 35.1		
(4.5)	
39.3	
(4.4)	
45.2	(6.1)	 0.010	 0.020	 0.020	
contra	mandible	 mean	(Gy)	 17.4	
(2.1)	
21.0	
(1.7)	
25.5	(3.8)	 0.004	 0.004	 0.002	
Contra	mandible	 D2%	(Gy)	 27.2	
(1.8)	
30.3	
(3.1)	
40.1	(7.3)	 0.014	 0.002	 0.002	
contra	parotid	 mean	(Gy)	 5.6	(1.9)	 15.9	
(4.9)	
11.8	(4.2)	 0.002	 0.009	 0.006	
Contra	SMG	 mean	(Gy)	 20.9	
(7.7)	
27.7	
(5.8)	
21.4	
(6.5)	 0.155	 0.734	 0.004	
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Table	3:		Predicted	NTCPs	for	3DCRT,	IMRT,	and	VMAT	plans	for	all	10	cases.		
Contralaretal	oral	cavity	sparing	volume	with	
36Gy	(mean	dose)	constraint	
	 	 	 	 	 	
Contra	oral	cavity	
	
mean	(Gy)	 35.1	
(4.5)	
34.6	
(4.7)	
37.2	(6.3)	 0.492	 0.322	 0.010	
contra	mandible	 mean	(Gy)	 17.4	
(2.1)	
18.4	
(2.7)	
20.5	(3.8)	 0.432	 0.037	 0.041	
Contra	mandible	 D2%	(Gy)	 27.2	
(1.8)	
27.3	
(3.4)	
30	(6.2)	 0.415	 0.011	 0.008	
Contra	parotid	 mean	(Gy)	 5.6	(1.9)	 14.7	
(4.8)	
10.3	(3.4)	 0.002	 0.014	 0.004	
Contra	SMG	 mean	(Gy)	 20.9	
(7.7)	
27.7	
(7)	
30.7	
(5.7)	 0.014	 0.027	 0.557	
	 3DCRT		 IMRT		 VMAT		 P-values,	Wilcoxon	signed-rank	test	
	NTCP	model	 Dose	Statistic	 Mean	
(SD)	
Mean	
(SD)	
Mean	
(SD)	
3DCRT	Vs	
IMRT	
3DCRT	Vs	
VMAT	
IMRT	Vs	
VMAT	
NCF	impairment	[12]	 EQD2	D40	bilateral	
hippocampi	
0.058	
(0.05)	
0.050	
(0.02)	
0.052	
(0.02)	
0.297	 0.051	 0.834	
Grade	3	dysphagia	[13]	 MD2Gy	oral	cavity	 0.23	
(0.08)	
0.30	
(0.08)	
0.38	
(0.09)	
0.032	 0.002	 0.009	
Grade	3	oral	mucositis	[13]	 MD2Gy	oral	cavity	 0.38	
(0.10)	
0.47	
(0.10)	
0.57	
(0.10)	
0.024	 0.002	 0.009	
Grade	3	dysphagia	[13]-	with	
constraint	
MD2Gy	oral	cavity	 0.23	
(0.08)	
0.22	
(0.10)	
0.27	
(0.09)	
0.375	 0.375	 0.010	
Grade	3	oral	mucositis	[13]-	
with	constraint	
MD2Gy	oral	cavity	 0.38	
(0.10)	
0.37	
(0.13)	
0.43	
(0.10)	
0.375	 0.412	 0.010	
Secondary	cancers	 Risk	by	Plateau	
Model	
0.080	
(0.008)	
0.091	
(0.015
)	
0.091	
(0.016)	
0.092	 0.160	 0.780	
Risk	by	D0=10Gy	
Model	
0.053	
(0.004)	
0.055	
(0.006
)	
0.056	
(0.008)	
0.444	 0.154	 0.202	
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Table	4:		Changes	in	dose	metrics	on	estimated	treatment	dose.	The	mean	change	across	
patients	is	quoted	with	the	range	represented	by	the	standard	deviation.	Statistically	
significant	p-values	(Wilcoxon	signed-rank	test)	are	shown	in	bold.	
 
	
 
	
	
	
	
	
	
	
	
	
	 	 Conventional	 IMRT	 VMAT	 	
	 	 Mean	(SD)	 p-value	 Mean	(SD)	 p-value	 Mean	(SD)	 p-value	
CTV	Primary	 D	95%	[Gy]	 -3.5	(2.0)	 0.008	 -1.9	(1.95)	 0.008	 -1.9	(1.7)	 0.008	
	 D	2	%	[Gy]	 +0.2(0.5)	 0.483	 -0.1	(0.59)	 0.547	 0.17	(0.8)	 0.844	
CTV	Nodes	 D	95%	[Gy]	 -2.0	(2.4)	 0.014	 -1	(2.19)	 0.383	 -0.97	(2)	 0.250	
Contralateral	
Parotid	
Mean	Dose	[Gy]	 -0.2	(0.3)	 0.091	 -0.1	(0.62)	 1.000	 -0.02	(0.4)	 1.000	
Ipsilateral	
Mandible	
Mean	Dose	[Gy]	 -0.1	(1.1)	 0.383	 -0.3	(0.87)	 0.250	 -0.18	(1.4)	 0.383	
Contralateral	
Mandible	
Mean	Dose	[Gy]	 +0.1	(0.4)	 0.461	 -0.1	(0.53)	 0.641	 -0.05	(0.6)	 0.944	
Oral	Cavity	 Mean	Dose	[Gy]	 +0.2	(0.6)	 0.195	 +0.1	(0.61)	 0.945	 0.10	(0.6)	 0.844	
Posterior	Fossa	 Mean	Dose	[Gy]	 +0.7	(1.2)	 0.052	 +0.8	(1.15)	 0.008	 0.67	(0.9)	 0.008	
Spinal	Cord	 D	0.1cm3	[Gy]	 -0.5	(1)	 0.250	 -0.5	(1.15)		 0.262	 -0.59	(1.1)	 0.109	
Brain	Stem	 D	0.1cm3	[Gy]	 +1.	(1.4)	 0.055	(1)	 +1	(1.4)	 0.016	 +0.8	(1.2)	 0.109	
